Missing a Dupixent Dose on an Every-14-Day Schedule
If you miss your every-2-week Dupixent dose, give the injection within 7 days of the missed dose and continue your original schedule; if more than 7 days have passed, give the injection immediately and restart a new every-2-week schedule from that point. 1
Immediate Dosing Instructions
The FDA-approved guidance provides clear parameters for managing missed doses on the every-2-week (Q2W) schedule 1:
- Within 7 days of missed dose: Administer the injection as soon as you remember, then resume your original schedule
- Beyond 7 days of missed dose: Administer the injection immediately and establish a new every-2-week schedule starting from that injection date
Clinical Consequences of Delayed Dosing
Disease Control Impact
Missing doses beyond the 7-day window may result in diminished disease control. Clinical trial data demonstrates that maintaining the every-2-week regimen is critical for sustained efficacy 2. In the SOLO-CONTINUE trial, patients who maintained their Q2W dosing showed negligible change in disease severity (-0.06% change in EASI improvement), while those with extended intervals experienced dose-dependent worsening 2.
What Happens with Extended Intervals
Real-world evidence shows that intentional dose spacing beyond Q2W leads to:
- Every 3-week dosing: Approximately 78-88% of well-controlled patients maintain response 3, 4
- Every 4-week dosing: Response rates drop further, with more patients requiring return to standard dosing 2, 3
- Unplanned gaps: May result in disease flare requiring re-establishment of control
The SOLO-CONTINUE trial found that patients on Q4W dosing experienced -3.84% worsening in EASI scores, and Q8W dosing showed -6.84% worsening, compared to placebo at -21.67% 2.
Practical Considerations
Antibody Formation Risk
Longer intervals between doses increase the risk of developing anti-drug antibodies, which can reduce treatment effectiveness 2. Treatment-emergent antibody incidence was:
- Q2W dosing: 4.3%
- Q4W dosing: 6.0%
- Q8W dosing: 11.7%
When Extended Intervals Might Be Considered
Extended dosing intervals should only be considered in patients with 3, 5:
- At least 40-52 weeks of successful Q2W treatment
- EASI score ≤4-7 for at least 6 months
- IgE levels <1,000 IU/mL
- Controlled disease activity
- This should be a planned, physician-supervised decision, not an accidental missed dose
Ocular Side Effects
Missing doses does not reduce the risk of dupilumab-related ocular surface disorders (DROSD) in the short term 6. DROSD typically presents within the first 4 months of treatment and affects approximately 25% of patients 6. The conjunctivitis rates were similar across different dosing intervals in clinical trials 2.
Key Pitfalls to Avoid
- Do not wait for your next scheduled dose if you've missed one—the 7-day window is critical
- Do not assume disease control will persist with irregular dosing—dupilumab has a specific pharmacokinetic profile requiring consistent dosing
- Do not intentionally extend intervals without physician guidance and documented disease control criteria
- Do not restart at a reduced frequency after a missed dose unless specifically directed by your physician
Bottom Line
The every-2-week schedule exists for pharmacologic reasons—maintaining therapeutic drug levels to block IL-4 and IL-13 signaling consistently 6. While some well-controlled patients may eventually taper to Q3W or Q4W under medical supervision, unplanned missed doses should be corrected promptly using the 7-day rule to maintain disease control and minimize the risk of flare 1.